Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction

被引:54
作者
Nakamura, Y
Yoshiyama, M
Omura, T
Yoshida, K
Izumi, Y
Takeuchi, K
Kim, S
Iwao, H
Yoshikawa, J
机构
[1] Osaka City Univ, Grad Sch Med, Dept Internal Med & Cardiol, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Pharmacol, Abeno Ku, Osaka 5458585, Japan
关键词
ACE inhibitors; adrenergic (ant)agonists; infarction; remodeling; ventricular function;
D O I
10.1016/S0008-6363(02)00644-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Angiotensin-converting enzyme (ACE) inhibitor and angiotensin 11 type I receptor blockers; (ARB) prevent cardiac remodeling after myocardial infarction (MI). However, it is controversial whether combination therapy of ACE inhibitor and ARB is more effective on cardiac remodeling than each agent alone. In this study, we compared the effects of an ACE inhibitor (temocapril), an ARB (CS-866), and their combination on cardiac remodeling after MI. Methods: Temocapril at 3 or 30 mg/kg/day, CS-866 at I or 10 mg/ka/day, or combined temocapril and CS-866 at 1.5 and 0.5 mg/kg/day or at 15 and 5 mg/kg/day, respectively, were administered to rats after MI. At 4 weeks after MI, we assessed hemodynamics, cardiac function by Doppler echocardiography and non-infarcted myocardial mRNA expression. Results: Animals treated with a combination of the two drugs had hemodynamics, heart weights and dimensions similar to the other treated animals. However, the combination of the two drugs suppressed ANP, BNP and other gene expressions related to contractile proteins of fetal type and collagens more effectively than ACE inhibitor or ARB alone. Conclusion: These data suggest that combination of the two drugs, independent of the hemodynamic effect, may improve left ventricular phenotypic change, collagen accumulation and diastolic function. (C) 2002 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:48 / 54
页数:7
相关论文
共 30 条
  • [1] THE CELL BIOLOGY OF TRANSFORMING GROWTH-FACTOR-BETA
    BARNARD, JA
    LYONS, RM
    MOSES, HL
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1032 (01) : 79 - 87
  • [2] TRANSFORMING GROWTH-FACTOR-BETA IN DISEASE - THE DARK SIDE OF TISSUE-REPAIR
    BORDER, WA
    RUOSLAHTI, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (01) : 1 - 7
  • [3] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    Cohn, JN
    Tognoni, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1667 - 1675
  • [4] INHIBITION BY ANGIOTENSIN-II TYPE-1 RECEPTOR ANTAGONIST OF CARDIAC PHENOTYPIC MODULATION AFTER MYOCARDIAL-INFARCTION
    HANATANI, A
    YOSHIYAMA, M
    KIM, SK
    OMURA, T
    TODA, I
    AKIOKA, K
    TERAGAKI, M
    TAKEUCHI, K
    IWAO, H
    TAKEDA, T
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1995, 27 (09) : 1905 - 1914
  • [5] The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats
    Higashiura, KS
    Ura, N
    Takada, T
    Li, Y
    Torii, T
    Togashi, N
    Takada, M
    Takizawa, H
    Shimamoto, K
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (03) : 290 - 297
  • [6] Effects of an AT(1) receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats
    Kim, S
    Ohta, K
    Hamaguchi, A
    Yukimura, T
    Miura, K
    Iwao, H
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (03) : 549 - 556
  • [7] Kim S, 2001, CIRCULATION, V103, P148
  • [8] KIM SK, 1995, J PHARMACOL EXP THER, V273, P509
  • [9] ANGIOTENSIN-II INDUCES CARDIAC PHENOTYPIC MODULATION AND REMODELING IN-VIVO IN RATS
    KIM, SK
    OHTA, K
    HAMAGUCHI, A
    YUKIMURA, T
    MIURA, K
    IWAO, H
    [J]. HYPERTENSION, 1995, 25 (06) : 1252 - 1259
  • [10] LINZ W, 1995, PHARMACOL REV, V47, P25